Lancaster-based biotech company Immunomic Therapeutics Inc. has received the go-ahead from federal regulators to conduct clinical trials of what it hopes will be its debut product, a DNA vaccine for people with allergies to Japanese red cedar pollen.

The U.S. Food and Drug Administration reviewed and approved Immunomic Therapeutics' investigational new drug application, the company said in a statement.

The application included Immunomic's own animal studies of the vaccine and other animal and human studies of the underlying technology. The FDA found no cause for concern, clearing the way for tests on human beings, the company said.

Enrollment has begun for its first round of clinical studies, expected to commence this summer in Atlanta, Immunomic Therapeutics said.

Immunomic Therapeutics has spent several years developing and testing the vaccine, known as JRC-LAMP-vax. The vaccine targets specific cell mechanisms as a way to intensify the body's immune response to allergy-causing substances.